Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

symbols : SPRO    save search

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
Published: 2024-03-13 (Crawled : 20:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 10.24% H: 3.28% C: -4.92%

business year update therapeutics results
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
Published: 2024-03-06 (Crawled : 13:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: -0.6% H: 4.22% C: 3.61%

report business year update therapeutics financial results
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 4.27% C: 1.22%

spr206 treat clearance infections therapeutics
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: -1.32% H: 5.37% C: 0.67%

conference therapeutics
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-31 (Crawled : 21:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 0.66% H: 3.27% C: 2.61%

nasdaq grants therapeutics
Spero Therapeutics Provides Corporate Update and 2024 Outlook
Published: 2024-01-05 (Crawled : 13:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 2.04% C: -2.72%

update therapeutics
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
Published: 2024-01-02 (Crawled : 13:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 5.44% C: 3.4%

first infections therapeutics
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 2.7% H: 7.89% C: -4.39%

business update therapeutics results
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
Published: 2023-11-06 (Crawled : 13:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 0.84% H: 1.67% C: -3.33%

report business update therapeutics financial results
Spero Therapeutics to Present at Upcoming November Investor Conferences
Published: 2023-11-01 (Crawled : 20:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 0.88% H: 0.87% C: -0.87%

therapeutics
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
Published: 2023-11-01 (Crawled : 12:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 2.78% H: 3.6% C: 2.7%

business therapeutics financial
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-10-31 (Crawled : 20:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 2.78% H: 3.6% C: 2.7%

nasdaq grants therapeutics
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-09-29 (Crawled : 20:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

nasdaq grants therapeutics
Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference
Published: 2023-09-20 (Crawled : 20:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 0.81% H: 0.0% C: -1.61%

conference global therapeutics
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
Published: 2023-09-12 (Crawled : 14:30) - biospace.com/
TCRX | $7.32 -5.55% 23K twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: -1.92% H: 7.06% C: 2.75%
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.0% C: -2.26%
PTCT | $25.58 -0.39% 280K twitter stocktwits trandingview |
Health Technology
| | O: -0.47% H: 1.2% C: 0.95%

life sciences therapeutics
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Published: 2023-09-06 (Crawled : 12:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 0.7% H: 1.02% C: -4.17%

conference global therapeutics
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-08-31 (Crawled : 20:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 0.67% H: 2.65% C: 0.66%

nasdaq grants therapeutics
Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update
Published: 2023-08-10 (Crawled : 20:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 1.38% H: 0.68% C: -4.76%

business update therapeutics results
Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Published: 2023-08-03 (Crawled : 12:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 2.28% H: 0.0% C: -3.82%

report business update therapeutics financial results
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr
Published: 2023-07-31 (Crawled : 12:00) - globenewswire.com
SPRO | $1.57 -4.27% 88K twitter stocktwits trandingview |
Health Technology
| | O: 9.15% H: 6.45% C: 5.16%

fda trial therapeutics agreement
Gainers vs Losers
53% 47%

Top 10 Gainers
WISA 4 | $7.86 349.14% 120M twitter stocktwits trandingview |
Electronic Technology

TPET | $0.4951 114.24% 29M twitter stocktwits trandingview |
n/a

PRSO | $1.99 56.69% 52M twitter stocktwits trandingview |
Manufacturing

PALI | $6.5 56.25% 22M twitter stocktwits trandingview |
Manufacturing

JAGX | $0.1767 48.74% 430M twitter stocktwits trandingview |
Health Technology

SXTC | $2.03 45.0% 27M twitter stocktwits trandingview |
Health Technology

SPCB | $0.3888 40.87% 27M twitter stocktwits trandingview |
Electronic Technology

DYNT | $0.52 40.39% 20M twitter stocktwits trandingview |
Health Technology

SNGX | $0.54 39.86% 7.3M twitter stocktwits trandingview |
Health Technology

BSGM | $1.53 39.09% 2.6M twitter stocktwits trandingview |
Health Technology


Your saved searches
Save your searches and get alerts when important news are released.